KRSA · Korsana Biosciences, Inc.
Cyclerion Therapeutics Inc (KRSA)
What's happening
- KRSA is up 4.10% today, trading at $32.12. — Live quote
- Volume today (5,237) is well below its 3-month average of 97,760. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.21 actual vs. $-0.39 estimated (+45.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $101.1M | $43.3M | $52.2M | $62.5M | $44.7M |
| P/E | -16.23 | -7.33 | -15.11 | -16.45 | -8.90 |
| Price/Sales | — | 41.28 | 41.96 | 169.76 | 162.39 |
| Price/Book | 19.88 | 6.38 | 5.47 | 7.29 | 5.09 |
| EV/Revenue | — | 38.59 | 38.28 | 161.60 | 149.15 |
| ROE | -122.51% | -86.97% | -36.19% | -44.32% | -57.13% |
| ROA | -89.93% | -69.44% | -33.14% | -40.53% | -50.94% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -2.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -170.1%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on KRSA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $875.0K | $93.0K | $81.0K | $194.0K | $0 | $0 |
| Operating income | -$1.8M | -$3.2M | -$1.0M | -$1.7M | -$1.5M | -$1.1M | -$1.4M | -$1.6M |
| Net income | -$1.8M | -$3.2M | -$976.0K | -$324.0K | -$1.4M | -$723.0K | -$1.3M | -$1.5M |
| EPS (diluted) | $-0.41 | $-0.76 | $-0.30 | $-0.11 | $-0.56 | $-0.29 | $-0.53 | $-0.62 |
| EPS (basic) | $-0.41 | $-0.76 | $-0.30 | $-0.11 | $-0.56 | $-0.29 | $-0.53 | $-0.62 |
| Operating margin | — | — | -$115 | -$1.8K | -$1.8K | -$581 | — | — |
| Net margin | — | — | -$112 | -$348 | -$1.8K | -$373 | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.9M | $8.5M | $10.0M | $10.4M | $9.4M | $9.8M | $9.6M | $8.9M |
| Stockholders' equity | $5.1M | $6.8M | $9.1M | $9.5M | $8.6M | $8.8M | $8.8M | $8.2M |
| Total current assets | $1.5M | $3.1M | $4.6M | $5.1M | $4.0M | $4.5M | $4.2M | $3.5M |
| Total current liabilities | $1.8M | $1.7M | $900.0K | $877.0K | $800.0K | $1.1M | $725.0K | $700.0K |
| Cash & equivalents | $1.4M | $2.8M | $3.2M | $4.6M | $3.0M | $3.6M | $3.2M | $2.9M |
| Accounts receivable | $0 | $0 | $1.0M | $100.0K | $525.0K | $581.0K | $556.0K | $44.0K |
| Other current assets | $11.0K | $11.0K | $11.0K | $11.0K | $27.0K | $21.0K | $16.0K | $11.0K |
| Property, plant & equipment | $66.0K | $66.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.6M | $457.0K | $508.0K | $480.0K | $462.0K | $483.0K | $390.0K | $304.0K |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$276.0M | -$274.2M | -$271.0M | -$270.2M | -$269.2M | -$268.9M | -$267.5M | -$268.0M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | $0 | $0 |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.4M | -$1.2M | -$1.6M | -$264.0K | -$503.0K | -$968.0K | $360.0K | -$1.7M |
| Investing cash flow | $0 | -$66.0K | — | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $0 | $825.0K | $251.0K | $1.8M | -$130.0K | $1.4M | $0 | $0 |
| Free cash flow | -$1.4M | -$1.2M | — | — | -$503.0K | -$968.0K | — | — |
| Capital expenditures | $0 | $66.0K | — | — | $0 | $0 | — | — |
| Share-based compensation | $51.0K | $58.0K | $95.0K | $118.0K | $114.0K | $114.0K | $122.0K | $138.0K |
| Change in accounts receivable | $0 | -$1.0M | $900.0K | -$425.0K | -$56.0K | $25.0K | $556.0K | $0 |
| Change in accounts payable | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297.0K | $3.9M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| EPS (diluted) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 |
| EPS (basic) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 |
| Operating margin | -$240 | -$181 | — | -$6.2K | -$1.4K |
| Net margin | -$170 | -$153 | — | -$14.8K | -$1.3K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
| Stockholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M |
| Total current assets | $4.6M | $4.2M | $8.0M | $14.8M | $55.5M |
| Total current liabilities | $900.0K | $725.0K | $2.1M | $7.6M | $11.1M |
| Cash & equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M |
| Accounts receivable | $1.0M | $556.0K | $0 | $96.0K | $100.0K |
| Other current assets | $11.0K | $16.0K | $11.0K | $537.0K | $468.0K |
| Property, plant & equipment | — | $0 | $0 | $0 | $65.0K |
| Other non-current assets | — | — | $0 | $2.0M | $2.4M |
| Accounts payable | $508.0K | $390.0K | $1.2M | $3.0M | $1.8M |
| Short-term debt | — | — | — | $3.5M | $3.5M |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$271.0M | -$267.5M | -$264.4M | -$259.2M | -$215.1M |
| Accumulated other comprehensive income (loss) | — | $0 | -$12.0K | -$20.0K | -$23.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Investing cash flow | — | $0 | $10.4M | $0 | $1.5M |
| Financing cash flow | $3.3M | $0 | $5.0M | $29.0K | $30.8M |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Capital expenditures | — | — | — | $0 | $7.0K |
| Share-based compensation | $441.0K | $625.0K | $1.1M | $6.3M | $9.6M |
| Change in accounts receivable | $444.0K | $556.0K | -$96.0K | -$4.0K | $100.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding KRSA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-05-19 to 2026-08-14
Recent transactions
- Most recent: CHICKO RHONDA M. (Chief Financial Officer) — Option exercise of 25,000 shares on 2026-08-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| CHICKO RHONDA M. | Chief Financial Officer | Option exercise | 2026-08-14 | 25,000 |
| Graul Regina Margaret | See Remarks | Option exercise | 2026-08-14 | 55,849 |
| Hecht Peter M | Reporting person | Derivative conversion | 2026-07-16 | 351,037 |
| Higgins Michael J | Reporting person | Grant / award | 2025-03-25 | 9,090 |
| Slate Path Capital LP | 10% owner | Open market sale | 2024-11-21 | 357,880 |
| MCGUIRE TERRANCE | Reporting person | Grant / award | 2023-11-30 | 5,000 |
| DESOUZA ERROL B | Reporting person | Grant / award | 2023-11-30 | 20,000 |
| Hyman Steven | Reporting person | Grant / award | 2023-11-30 | 20,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-14 | CHICKO RHONDA M. | Chief Financial Officer | Option exercise | 25,000 | $2.35 |
| 2026-08-14 | Graul Regina Margaret | See Remarks | Option exercise | 55,849 | $3.30 |
| 2026-08-14 | Graul Regina Margaret | See Remarks | Tax withholding | 48,629 | $3.79 |
| 2026-07-16 | Hecht Peter M | Reporting person | Derivative conversion | 351,037 | — |
| 2025-03-25 | Hecht Peter M | Reporting person | Grant / award | 181,818 | $2.75 |
| 2025-03-25 | Higgins Michael J | Reporting person | Grant / award | 9,090 | $2.75 |
| 2024-11-21 | Slate Path Capital LP | 10% owner | Open market sale | 357,880 | $1.55 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-11 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-20 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about KRSA (Korsana Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Korsana Biosciences (KRSA) Stock Price, News & Analysis
Stock Titan · 2026-10-19 -
Net current asset value per share of Korsana Biosciences, Inc. – NASDAQ:KRSA
TradingView · 2026-10-16 -
A 25,974-share stake in Korsana Biosciences (KRSA) is held by J. Wood Capital Advisors.
Stock Titan · 2026-10-15 -
Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run
Yahoo Finance · 2026-10-02 -
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Seeking Alpha · 2026-09-17 -
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Yahoo Finance · 2026-09-08 -
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Seeking Alpha · 2026-04-01 -
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression - Slideshow
Seeking Alpha · 2026-01-07
No headlines in this category right now — try “All”.